CFDE Data Portal | Search ATXN2-AS

	Label	Description
	ATXN2-AS Gene (Entity type)	ENSG00000258099 - ATXN2 antisense RNA
	GSE135350 2 V 4 DEXAMETHASONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 2 v 13 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE48812 0 V 10 SULFORAPHANE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE125014 enzalutamide prostate gland 1 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE48812 sulforaphane 2 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE195568 palbociclib 1 v 10 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE206931 WDR5 inhibition WIN 3 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE125014 1 V 5 ENZALUTAMIDE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE185519 3 V 7 GILTERITINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS

ATXN2-AS

ENSG00000258099 - ATXN2 antisense RNA

GSE135350 2 V 4 DEXAMETHASONE HUMAN UP

A Gene Set from LINCS

GSE111247 temozolomide LN-308 2 v 13 human up

A Gene Set from LINCS

GSE48812 0 V 10 SULFORAPHANE HUMAN UP

A Gene Set from LINCS

GSE125014 enzalutamide prostate gland 1 v 5 human up

A Gene Set from LINCS

GSE48812 sulforaphane 2 v 5 human up

A Gene Set from LINCS

GSE195568 palbociclib 1 v 10 human up

A Gene Set from LINCS

GSE206931 WDR5 inhibition WIN 3 v 6 human up

A Gene Set from LINCS

GSE125014 1 V 5 ENZALUTAMIDE HUMAN UP

A Gene Set from LINCS

GSE185519 3 V 7 GILTERITINIB HUMAN DN

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.